Gentherm Incorporated
Gentherm Incorporated sells vehicle climate comfort systems, including seat heaters, thermoelectric devices and integrated electronic control units, to light vehicle OEMs, first-tier suppliers and aftermarket distributors by designing, developing and manufacturing thermal management technologies. Gentherm Incorporated sells battery thermal management solutions for various automotive battery types to light vehicle OEMs and first-tier suppliers by designing, developing and manufacturing thermal management technologies. Gentherm Incorporated sells patient temperature management systems, including conductive air-free warming and patient-securement technology, by designing, developing and manufacturing medical temperature management products. Gentherm Incorporated sells thermal comfort products to furniture brands.
LOCKED
Market: NormalKey Catalysts & Risks
The dominant catalyst is the completion and integration of the Modine Performance Technologies combination, which closed at the start of the fourth quarter of 2026 and reshapes Gentherm's end-market mix away from sole reliance on light vehicle production toward commercial vehicle, off-highway, power generation and other flow-management markets; the effect is two-sided, since delivering the cost synergies and the identified cross-selling opportunities would support margin expansion toward management's stated ambition, while integration missteps, higher leverage or loss of focus would pressure the multiple. Margin recovery is a second catalyst, with management guiding to a weaker third quarter followed by a rebound driven by footprint actions, customer recovery of inflation and richer mix from lumbar and massage comfort solutions; persistent warranty accruals or unrecovered tariff costs would undermine that path. Medical is a third catalyst, with clearance of the ThermAffyx patient warming system, the small acquisition of Innovative Medical Equipment and expected initial product revenue that could turn the segment from a drag into a visible growth contributor over the next two to three years. Capital returns are a further swing factor now that a substantially larger multi-year repurchase authorization is in place and management has indicated it expects to be active in the market after the transaction closes, which could support per-share outcomes if cash generation holds. Most of these items are corroborated by issuer materials and filings rather than relying on third-party reporting alone.
The most structural exposure is Gentherm's dependence on light vehicle production: even after the Modine combination a majority of revenue remains tied to automotive programs, leaving the company exposed to production cuts, platform cancellations and OEM cost-down pressure that are outside its control and can compress margins durably. Trade policy is a persistent structural cost and demand variable, with the company's own risk disclosures flagging tariffs, duties and shifting trade rules as material factors affecting input costs, customer ordering and plant loading. Medical carries an impairment overhang because the reporting unit's fair value cushion over carrying value is described as relatively limited, and recurring warranty accruals across automotive and medical indicate quality and cost-recovery friction that can resurface. Acquiring Modine Performance Technologies through a Reverse Morris Trust raises leverage and integration complexity, so the combined entity's ability to deleverage while funding organic growth and buybacks is a key medium-term risk to the equity case.
Research refreshed: 5th of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| Adient plc (ADNT) | 2.84B | 29.18 | 3.35 | -1.0% |
| BorgWarner … (BWA) | 14B | 29.81 | 2.22 | 1.7% |
| Dana Incorp… (DAN) | 4.66B | N.M. | — | -27.1% |
| Lear Corpor… (LEA) | 8.59B | 11.26 | 2.61 | -0.2% |
| Modine Manu… (MOD) | 10.1B | 67.38 | 1.65 | 23.1% |
| Gentherm In… (THRM) | 1.11B | 37.29 | 1.90 | 2.6% |
AI Opinion
Fundamentals
HOLD: Automotive execution is stronger than the headline cyclical backdrop, but sustainable profit conversion remains unproven. Q2 revenue grew 11%, or 9.5% excluding FX, driven by launches, volumes and take rates; lumbar and massage grew 38%. Raised standalone guidance and more than $1 billion of first-half awards support demand visibility, although awards are not current revenue. The newly completed Modine combination shifts the investment case toward integration and margin recovery; legacy valuation and financial metrics are not verified pro forma.
Peer Comparison
Gentherm ranks above approximately two-thirds of three quantified peers on combined growth and quality, but absolute profitability remains weak. Peer fair value of $21.45 implies 31.5% downside from $31.30, versus historical median fair value of $38.15 implying 21.9% upside. The historical low fair value of $30.61 offers little cushion, and the newly combined company's comparability with legacy peers and historical multiples requires reassessment.
Macro Environment
High vehicle-financing costs, a 5.28% Treasury yield and weak consumer demand constrain automotive production and valuation support. However, management forecasts approximately 5% standalone revenue growth against a 3% light-vehicle production decline, supported by launches and higher take rates; China operating strength also contradicts treating weak China equity proxies as company demand evidence. Modine is expected to reduce light-vehicle exposure from approximately 97% to roughly 63%, mitigating rather than eliminating cyclicality. Tariffs, inflation and delayed customer cost recovery are more direct margin risks than broad sector momentum.
Key Metrics
Revenue growth 8.7%, ROIC 3.15%, reported ratio-set operating margin 3.74% and FCF margin 2.61% indicate growth with weak capital efficiency. Current historical EV/EBITDA of 8.52x versus an 11.77x historical median suggests rerating potential, but deteriorating margins justify some discount. Q2 adjusted EBITDA margin of 11.7% versus roughly 12% FY2026 guidance is the immediate operating benchmark; post-close leverage, share count and cash conversion are the critical missing valuation inputs.
Insider Activity
Slightly bearish but low-information: two officer sales totaling $243,056 occurred 30-90 days ago, reducing their positions by 14.6% and 16.0%. No trades occurred in the latest 30 days, no CEO/CFO trades or qualifying cluster were observed, and sale-plan status is unclassified. Not a recommendation driver.
Income Statement
Sales momentum exceeds profit momentum: TTM revenue increased 8.68%, while operating income fell 34.46% to $63.6 million; Q2 operating margin declined to 2.57%. Q2 adjusted EPS rose 39% to $0.75, but adjusted EBITDA margin fell to 11.7% from 12.2%, and GAAP EPS was $0.14 after approximately $0.55 per share of merger and restructuring expenses. These charges explain part, not all, of the weakness: inflation-recovery timing, warranty accruals and overhead growth remain material. Standalone FY2026 EBITDA guidance of $185 million-$200 million requires the anticipated Q4 margin rebound.
Cash Flow
TTM FCF of $41.2 million implies approximately 4.3% yield on the supplied legacy market capitalization, but both Q1 and Q2 GAAP FCF were negative. Receivables consumed $43.7 million of TTM cash, including $31.8 million in Q2, while inventory consumed another $12.6 million. Management reported approximately $16 million of first-half adjusted FCF and guided to $85 million-$100 million for FY2026, requiring substantial second-half conversion; adjusted guidance is not directly interchangeable with GAAP FCF. Positive quarterly GAAP FCF and lower receivables outflows without additional borrowing are essential confirmation.
Balance Sheet
Legacy liquidity is adequate: cash $213.2 million, debt $273.3 million, net debt $60.1 million and current ratio approximately 2.1x, plus $51.8 million of lease commitments. Q2 reported liquidity was $502 million and net leverage 0.3x. Management expected approximately 1x net leverage at transaction closing and secured $800 million of committed financing, but actual post-close debt and share count are not supplied; pre-close balance-sheet strength should not be extrapolated unchanged.